Drug Trial Radar · NCT01439984
Trial of PED-1 in Male Patients With Premature Ejaculation
Last checked: Nov 20, 2026Latest source record: Oct 3, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
159
Actual
Start
Sep 2011
Primary completion
Jun 2012
Study completion Jun 2012
Sponsor
- Lead sponsor
- SymyooIndustry
- Sponsor type
- Industry
- First posted
- Sep 23, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 20 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate whether PED-1 is more effective than Placebo in the treatment of premature ejaculation.
Conditions
- Premature Ejaculation
Interventions
ClomipramineDrug
Clomipramine 15 mg tablet or placebo tablet on demand for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intravaginal ejaculation latency time (IELT)(seconds)Time frame: 12 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Ewha Womans University Mokdong Hospital
Seoul, South Korea
Seoul St.Marry's Hospital
Seoul, South Korea
Inje University Ilsan Paik Hospital
Goyang-si, Gyeonggi-do, South Korea
National Health Insurance Corporation Ilsan Hospital
Goyang-si, Gyeonggi-do, South Korea
Uijeongbu St.Marry's Hospital
Uijeongbu-si, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.